By Professor Glenda Halliday

Book Chapters

Halliday GM; Cullen KM, 1995, 'Cytoarchitecture and Chemistry of the Human Ascending Cholinergic System', in Tracey DJ; Paxinos G; Stone J (ed.), Neurotransmitters in the human brain, Plenum Pub Corp, pp. 129 - 153

Halliday GM; Cullen K, 1995, 'Neurotransmitter changes in Alzheimer's disease', in Tracey DJ; Paxinos G; Stone J (ed.), Neurotransmitters in the human brain: Conference in Honour of Istvan Tork, Plenum Press, New York, pp. 199 - 219

Halliday GM; Harding AJ; Paxinos G, 1995, 'Serotonin and tachykinin systems', in The Rat Nervous System, Academic Press, Sydney, pp. 929 - 974

Halliday GM; Brooks W; Harper C; Broe G; Creasey H, 1993, 'Neuropathological Correlates of Population-Based Studies of Neurodegenerative Diseases', in Beregi E; Gergely IA; Rajczi K (ed.), Recent Advances in Aging Science, Monduzzi, pp. 667 - 671

Halliday GM; Cotton RGH; Tork I; Blumbergs PC; Blessing WW; Geffen LB, 1991, 'Serotonergic neurons in Parkinson’s disease using antibody PH8 to phenylalanine hydroxylase', in Blau N; Curtius HC; Levine RA; Cotton RGH (ed.), Pteridines and related biogenic amines, Walter de Gruyter & Co., Berlin, pp. 283 - 290

PEARSON J; HALLIDAY G; SAKAMOTO N; MICHEL J-P, 1990, 'Catecholaminergic Neurons', in The Human Nervous System, Elsevier, pp. 1023 - 1049, http://dx.doi.org/10.1016/b978-0-12-547625-6.50036-2

Halliday GM; Pearson J; Sakamoto N; Michel JP, 1990, 'Human Catecholaminergic Neurons', in Paxinos G (ed.), The Human Nervous System, Academic Press, San Diego, pp. 1023 - 1050

PAXINOS G; TÖRK I; HALLIDAY G; MEHLER WR, 1990, 'Human Homologs to Brainstem Nuclei Identified in Other Animals as Revealed by Acetylcholinesterase Activity', in The Human Nervous System, Elsevier, pp. 149 - 202, http://dx.doi.org/10.1016/b978-0-12-547625-6.50012-x

Halliday GM; Paxinos G; Törk I; Mehler RW, 1990, 'Progress in catecholamine research. Part B: Central aspects. Neurology and Neurobiology', in Paxinos G (ed.), The Human Nervous System, Academic Press, San Diego, pp. 149 - 202

Halliday GM; Li Y; Joh T; Cotton RGH; Geffen LB; Blessing WW, 1989, 'Modulation of sensorimotor activity during alterations in behavioural states', in Sandler M; Dahlstrom A (ed.), Progress in Catecholamine Research Central Aspects, Alan R. Liss, New York, pp. 179 - 185

Halliday GM; Tork I; Scheibner T; Turner S, 1984, 'The organization and connections of the mesencephalic ventromedial tegmentum', in Bandler R (ed.), Modulation of sensorimotor activity during alterations in behavioral states proceedings of a satellite symposium of the XXIX Congress of the International Union of Physiological Sciences on modulation of sensorimotor activity during altered behavioral states, held at Cedar Lake, Queensland, Australia, September 4-8, 1983, Alan R. Liss, New York, pp. 39 - 73

Journal articles

Wiseman JA; Turner CP; Faull RLM; Halliday GM; Dieriks BV, 2025, 'Refining α-synuclein seed amplification assays to distinguish Parkinson’s disease from multiple system atrophy', Translational Neurodegeneration, 14, http://dx.doi.org/10.1186/s40035-025-00469-6

Beauchamp LC; Ellett LJ; Juan SMA; Liu XM; Hunt CPJ; Parish CL; Jacobson LH; Shepherd CE; Halliday GM; Bush AI; Vella LJ; Finkelstein DI; Barnham KJ, 2025, 'Evidence of COMT dysfunction in the olfactory bulb in Parkinson’s disease', Acta Neuropathologica, 149, http://dx.doi.org/10.1007/s00401-025-02861-y

Filimontseva A; Fu YH; Vila M; Halliday GM, 2025, 'Neuromelanin and selective neuronal vulnerability to Parkinson's disease', Trends in Neurosciences, 48, pp. 445 - 459, http://dx.doi.org/10.1016/j.tins.2025.04.005

De Boer SCM; Fenoglio C; Arighi A; Wissink L; Riedl L; Rue I; Landin-Romero R; Matis S; Chatterton Z; Halliday GM; Diehl-Schmid J; Piguet O; Verberk IMW; Teunissen CE; Ducharme S; Van Der Lee SJ; Pijnenburg YAL; Galimberti D, 2025, 'Serum neurofilament light is superior to glial fibrillary acidic protein to distinguish sporadic frontotemporal dementia from late-onset primary psychiatric disorders: a retrospective DIPPA-FTD study', BMJ Neurology Open, 7, http://dx.doi.org/10.1136/bmjno-2024-001007

Kavanagh T; Thierry M; Balcomb K; Ponce J; Kanshin E; Tapia-Sealey A; Halliday G; Ueberheide B; Wisniewski T; Drummond E, 2025, 'The interactome of tau phosphorylated at T217 in Alzheimer’s disease human brain tissue', Acta Neuropathologica, 149, http://dx.doi.org/10.1007/s00401-025-02881-8

Matar E; Halliday GM, 2025, 'Biological effects of pathologies in Lewy body diseases: why timing matters', Lancet Neurology, 24, pp. 441 - 455, http://dx.doi.org/10.1016/S1474-4422(25)00085-7

Kavanagh T; Balcomb K; Ahmadi Rastegar D; Lourenco GF; Wisniewski T; Halliday G; Drummond E, 2025, 'hnRNP A1, hnRNP A2B1, and hnRNP K are dysregulated in tauopathies, but do not colocalize with tau pathology', Brain Pathology, 35, http://dx.doi.org/10.1111/bpa.13305

Pottier C; Küçükali F; Baker M; Batzler A; Jenkins GD; van Blitterswijk M; Vicente CT; De Coster W; Wynants S; Van de Walle P; Ross OA; Murray ME; Faura J; Haggarty SJ; van Rooij JG; Mol MO; Hsiung GYR; Graff C; Öijerstedt L; Neumann M; Asmann Y; McDonnell SK; Baheti S; Josephs KA; Whitwell JL; Bieniek KF; Forsberg L; Heuer H; Lago AL; Geier EG; Yokoyama JS; Oddi AP; Flanagan M; Mao Q; Hodges JR; Kwok JB; Domoto-Reilly K; Synofzik M; Wilke C; Onyike C; Dickerson BC; Evers BM; Dugger BN; Munoz DG; Keith J; Zinman L; Rogaeva E; Suh ER; Gefen T; Geula C; Weintraub S; Diehl-Schmid J; Farlow MR; Edbauer D; Woodruff BK; Caselli RJ; Donker Kaat LL; Huey ED; Reiman EM; Mead S; King A; Roeber S; Nana AL; Ertekin-Taner N; Knopman DS; Petersen RC; Petrucelli L; Uitti RJ; Wszolek ZK; Ramos EM; Grinberg LT; Tempini MLG; Rosen HJ; Spina S; Piguet O; Grossman M; Trojanowski JQ; Keene CD; Jin LW; Prudlo J; Geschwind DH; Rissman RA; Cruchaga C; Ghetti B; Halliday GM; Beach TG; Serrano GE; Arzberger T; Herms J; Boxer AL; Honig LS; Vonsattel JP; Lopez OL; Kofler J; White CL; Gearing M; Glass J; Rohrer JD; Irwin DJ; Lee EB, 2025, 'Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing', Nature Communications, 16, pp. 3914, http://dx.doi.org/10.1038/s41467-025-59216-0

Fu YH; Adler GL; Youssef P; Phan K; Halliday GM; Dzamko N; Kim WS, 2025, 'Human Endogenous Retrovirus K in Astrocytes Is Altered in Parkinson's Disease', Movement Disorders, 40, pp. 683 - 692, http://dx.doi.org/10.1002/mds.30128

Lewis SJG; Sue CM; Cooper A; Halliday GM, 2025, 'Future is now: An Australasian perspective on disease-modifying trials in Parkinson's and prodromal disease', BMJ Neurology Open, 7, http://dx.doi.org/10.1136/bmjno-2025-001070

Kulisevsky J; Litvan I; Weintraub D; Goldman JG; Tröster AI; Lewis SJG; Adler C; Alves G; Amami P; Anderson T; Barker R; Barone P; Bezdicek O; Biundo R; Breen D; Burn D; Camacho M; Cammisuli D; Caviness J; Cecilia R; Cholerton B; Dalrymple-Alford J; de Bie R; Duff-Canning S; Eslinger P; Farrer M; Gasca-Salas C; Geurtsen G; Gunzler S; Halliday G; Huang X; Bilbao NI; Leverenz J; Marras C; Matar E; Mollenhauer B; Junque C; Pedersen K; Ricciardi L; Rodríguez-Oroz M; Santangelo G; Schiehser D; Segura B; Weil R; Williams-Gray C; Wu RMR; Yarnall A; Yu RL; Zabetian C, 2025, 'A Call for Change: Updating the Operational Definition for Dementia in Parkinson's Disease', Movement Disorders Clinical Practice, 12, pp. 296 - 301, http://dx.doi.org/10.1002/mdc3.14305

Suzuki M; Nilsson S; Shepherd CE; Zammit I; Suryana E; Mueller N; Halliday G; Wang X; Symeonides C; Dunlop S; Mueller JF, 2025, 'Number of Carbons Is a Critical Parameter for Accumulation of Per- and Polyfluoroalkyl Substances in the Human Brain', Environmental Science and Technology, 59, pp. 3366 - 3375, http://dx.doi.org/10.1021/acs.est.4c09458

Lam I; Ndayisaba A; Lewis AJ; Fu YH; Sagredo GT; Kuzkina A; Zaccagnini L; Celikag M; Sandoe J; Sanz RL; Vahdatshoar A; Martin TD; Morshed N; Ichihashi T; Tripathi A; Ramalingam N; Oettgen-Suazo C; Bartels T; Boussouf M; Schäbinger M; Hallacli E; Jiang X; Verma A; Tea C; Wang Z; Hakozaki H; Yu X; Hyles K; Park C; Wang X; Theunissen TW; Wang H; Jaenisch R; Lindquist S; Stevens B; Stefanova N; Wenning G; van de Berg WDJ; Luk KC; Sanchez-Pernaute R; Gómez-Esteban JC; Felsky D; Kiyota Y; Sahni N; Yi SS; Chung CY; Stahlberg H; Ferrer I; Schöneberg J; Elledge SJ; Dettmer U; Halliday GM; Bartels T; Khurana V, 2025, 'Erratum: Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions (Neuron (2024) 112(17) (2886–2909.e16), (S0896627324004094), (10.1016/j.neuron.2024.06.002))', Neuron, 113, pp. 637, http://dx.doi.org/10.1016/j.neuron.2025.01.018

Wiseman JA; Halliday GM; Dieriks BV, 2025, 'Neuronal α-synuclein toxicity is the key driver of neurodegeneration in multiple system atrophy.', Brain, http://dx.doi.org/10.1093/brain/awaf030

Espay AJ; Lees AJ; Cardoso F; Frucht SJ; Erskine D; Sandoval IM; Bernal-Conde LD; Sturchio A; Imarisio A; Hoffmann C; Montemagno KT; Milovanovic D; Halliday GM; Manfredsson FP, 2025, 'The α-synuclein seed amplification assay: Interpreting a test of Parkinson's pathology', Parkinsonism and Related Disorders, 131, http://dx.doi.org/10.1016/j.parkreldis.2024.107256

Ndayisaba A; Halliday GM; Khurana V, 2025, 'Multiple System Atrophy: Pathology, Pathogenesis, and Path Forward', Annual Review of Pathology Mechanisms of Disease, 20, pp. 245 - 273, http://dx.doi.org/10.1146/annurev-pathmechdis-051122-104528

Espay AJ; Lees AJ; Cardoso F; Frucht SJ; Erskine D; Sturchio A; Imarisio A; Hoffmann C; Montemagno KT; Naudi-Fabra S; Milovanovic D; Halliday GM; Manfredsson FP, 2025, 'Alpha-synuclein in Parkinson's disease: Embracing debate, exercising skepticism', Parkinsonism and Related Disorders, http://dx.doi.org/10.1016/j.parkreldis.2025.107874

Fu YH; Halliday GM, 2025, 'Dementia with Lewy bodies and Parkinson disease dementia — the same or different and is it important?', Nature Reviews Neurology, http://dx.doi.org/10.1038/s41582-025-01090-x

Isik FI; Fu YH; Pickford R; Cheng Q; Yang Y; Lewis SJG; Dzamko N; Halliday GM; Kim WS, 2025, 'Dysregulation of Monounsaturated Fatty Acids is Related to α-Synuclein in Multiple System Atrophy', Movement Disorders, http://dx.doi.org/10.1002/mds.30248

Afaar F; Youssef P; Galper J; Chua M; Halliday GM; Lewis SJG; Dzamko N, 2025, 'Peripheral Mononuclear Cell Mitochondrial Function Associates with T-Cell Cytokines in Parkinson's Disease', Movement Disorders, http://dx.doi.org/10.1002/mds.30233

de Boer SCM; Riedl L; Braak S; Fenoglio C; Foxe D; Carrick J; Landin-Romero R; Matis S; Chatterton Z; Rue I; van Engelen M-PE; Fieldhouse JLP; Oudega M; Schouws SNTM; Krudop WA; van Harten AC; Duits FH; van der Lee SJ; Galimberti D; Diehl-Schmid J; Halliday GM; Ducharme S; Pijnenburg YAL; Piguet O, 2025, 'Differentiating sporadic frontotemporal dementia from late-onset primary psychiatric disorders.', Brain Commun, 7, pp. fcaf199, http://dx.doi.org/10.1093/braincomms/fcaf199

Afaar F; Youssef P; Galper J; Chua M; Halliday GM; Lewis S; Dzamko N, 2025, 'Mitochondrial impairments in mononuclear cells are associated with inflammation in Parkinson’s disease.', Parkinsonism & Related Disorders, 134, pp. 107422 - 107422, http://dx.doi.org/10.1016/j.parkreldis.2025.107422

Wiseman JA; Halliday GM; Dieriks BV, 2024, 'A new seed amplification assay to diagnose multiple system atrophy', Lancet Neurology, 23, pp. 1175 - 1176, http://dx.doi.org/10.1016/S1474-4422(24)00428-9

Naaldijk Y; Fernández B; Fasiczka R; Fdez E; Leghay C; Croitoru I; Kwok JB; Boulesnane Y; Vizeneux A; Mutez E; Calvez C; Destée A; Taymans JM; Aragon AV; Yarza AB; Padmanabhan S; Delgado M; Alcalay RN; Chatterton Z; Dzamko N; Halliday G; Ruiz-Martínez J; Chartier-Harlin MC; Hilfiker S, 2024, 'A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells', Npj Parkinson S Disease, 10, http://dx.doi.org/10.1038/s41531-023-00624-8

Fu YH; Pickford R; Galper J; Phan K; Wu P; Li H; Kim YB; Dzamko N; Halliday GM; Kim WS, 2024, 'A protective role of ABCA5 in response to elevated sphingomyelin levels in Parkinson’s disease', Npj Parkinson S Disease, 10, http://dx.doi.org/10.1038/s41531-024-00632-2

Weiss F; Hughes L; Fu Y; Bardy C; Halliday GM; Dzamko N, 2024, 'Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model', Translational Neurodegeneration, 13, http://dx.doi.org/10.1186/s40035-024-00448-3

Balcomb K; Johnston C; Kavanagh T; Halliday GM; Wisniewski T; Sunde M; Drummond E, 2024, 'Basic Science and Pathogenesis', Alzheimer's & dementia : the journal of the Alzheimer's Association, 20, pp. e090551, http://dx.doi.org/10.1002/alz.090551

Kovacs GG; Grinberg LT; Halliday G; Alafuzoff I; Dugger BN; Murayama S; Forrest SL; Martinez-Valbuena I; Tanaka H; Kon T; Yoshida K; Jaunmuktane Z; Spina S; Nelson PT; Gentleman S; Alegre-Abarrategui J; Serrano GE; Paes VR; Takao M; Wakabayashi K; Uchihara T; Yoshida M; Saito Y; Kofler J; Rodriguez RD; Gelpi E; Attems J; Crary JF; Seeley WW; Duda JE; Keene CD; Woulfe J; Munoz D; Smith C; Lee EB; Neumann M; White CL; McKee AC; Thal DR; Jellinger K; Ghetti B; Mackenzie IRA; Dickson DW; Beach TG, 2024, 'Biomarker-Based Approach to α-Synucleinopathies: Lessons from Neuropathology', Movement Disorders, 39, pp. 2173 - 2179, http://dx.doi.org/10.1002/mds.30028

de Boer SCM; Fenoglio C; Fumagalli GG; Riedl L; Matis S; Chatterton Z; Rue I; Landin-Romero R; van der Lee SJ; Sommer P; Grimmer T; Diehl-Schmid J; Teunissen C; Galimberti D; Halliday GM; Ducharme S; Piguet O; Pijnenburg YAL, 2024, 'Clinical Manifestations', Alzheimer's & dementia : the journal of the Alzheimer's Association, 20, pp. e087999, http://dx.doi.org/10.1002/alz.087999

Luo H; Gustavsson EK; Macpherson H; Dominik N; Zhelcheska K; Montgomery K; Anderson C; Yau WY; Efthymiou S; Turner C; DeTure M; Dickson DW; Josephs KA; Revesz T; Lashley T; Halliday G; Rowe DB; McCann E; Blair I; Lees AJ; Tienari PJ; Suomalainen A; Molina-Porcel L; Kovacs GG; Gelpi E; Hardy J; Haltia MJ; Tucci A; Jaunmuktane Z; Ryten M; Houlden H; Chen Z, 2024, 'Letter to the editor on: Hornerin deposits in neuronal intranuclear inclusion disease: direct identification of proteins with compositionally biased regions in inclusions by Park et al. (2022)', Acta Neuropathologica Communications, 12, http://dx.doi.org/10.1186/s40478-023-01706-7

Jensen NM; Fu YH; Betzer C; Li H; Elfarrash S; Shaib AH; Krah D; Vitic Z; Reimer L; Gram H; Buchman V; Denham M; Rizzoli SO; Halliday GM; Jensen PH, 2024, 'MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity', Npj Parkinson S Disease, 10, http://dx.doi.org/10.1038/s41531-024-00841-9

Wiseman JA; Fu YH; Faull RLM; Turner CP; Curtis MA; Halliday GM; Dieriks BV, 2024, 'N-terminus α-synuclein detection reveals new and more diverse aggregate morphologies in multiple system atrophy and Parkinson’s disease', Translational Neurodegeneration, 13, http://dx.doi.org/10.1186/s40035-024-00456-3

Galper J; Mori G; McDonald G; Ahmadi Rastegar D; Pickford R; Lewis SJG; Halliday GM; Kim WS; Dzamko N, 2024, 'Prediction of motor and non-motor Parkinson’s disease symptoms using serum lipidomics and machine learning: a 2-year study', Npj Parkinson S Disease, 10, http://dx.doi.org/10.1038/s41531-024-00741-y

Balcomb K; Johnston C; Kavanagh T; Leitner D; Schneider J; Halliday G; Wisniewski T; Sunde M; Drummond E, 2024, 'SMOC1 colocalizes with Alzheimer’s disease neuropathology and delays Aβ aggregation', Acta Neuropathologica, 148, http://dx.doi.org/10.1007/s00401-024-02819-6

Burré J; Edwards RH; Halliday G; Lang AE; Lashuel HA; Melki R; Murayama S; Outeiro TF; Papa SM; Stefanis L; Woerman AL; Surmeier DJ; Kalia LV; Takahashi R; Olsen A; Surmeier DJ; Bayram E; Chaing HL; Lee JY; Peall K; Lohmann K; Zeuner K; Cornejo-Olivas M; Calabresi P; Przedborski S, 2024, 'Research Priorities on the Role of α-Synuclein in Parkinson's Disease Pathogenesis', Movement Disorders, 39, pp. 1663 - 1678, http://dx.doi.org/10.1002/mds.29897

Lam I; Ndayisaba A; Lewis AJ; Fu YH; Sagredo GT; Kuzkina A; Zaccagnini L; Celikag M; Sandoe J; Sanz RL; Vahdatshoar A; Martin TD; Morshed N; Ichihashi T; Tripathi A; Ramalingam N; Oettgen-Suazo C; Bartels T; Boussouf M; Schäbinger M; Hallacli E; Jiang X; Verma A; Tea C; Wang Z; Hakozaki H; Yu X; Hyles K; Park C; Wang X; Theunissen TW; Wang H; Jaenisch R; Lindquist S; Stevens B; Stefanova N; Wenning G; van de Berg WDJ; Luk KC; Sanchez-Pernaute R; Gómez-Esteban JC; Felsky D; Kiyota Y; Sahni N; Yi SS; Chung CY; Stahlberg H; Ferrer I; Schöneberg J; Elledge SJ; Dettmer U; Halliday GM; Bartels T; Khurana V, 2024, 'Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions', Neuron, 112, pp. 2886 - 2909.e16, http://dx.doi.org/10.1016/j.neuron.2024.06.002

Sagredo GT; Tanglay O; Shahdadpuri S; Fu YH; Halliday GM, 2024, '⍺-Synuclein levels in Parkinson's disease – Cell types and forms that contribute to pathogenesis', Experimental Neurology, 379, http://dx.doi.org/10.1016/j.expneurol.2024.114887

Carroll J; McCann H; Halliday GM; Kwok JB; Dobson-Stone C; Shepherd CE, 2024, 'Poly-GA immunohistochemistry is a reliable tool for detecting C9orf72 hexanucleotide repeat expansions', Brain Pathology, 34, http://dx.doi.org/10.1111/bpa.13216

Clarke AJ; Brodtmann A; Irish M; Mowszowski L; Radford K; Naismith SL; Mok VCT; Kiernan MC; Halliday GM; Ahmed RM, 2024, 'Risk factors for the neurodegenerative dementias in the Western Pacific region', Lancet Regional Health Western Pacific, 50, http://dx.doi.org/10.1016/j.lanwpc.2024.101051

Back to profile page